- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 12.03. | Inizio Ignite announces key leadership appointments | ||
| 11.03. | Incyte's Opzelura approved by NICE for patients with non-segmental vitiligo on the NHS | ||
| 11.03. | Commit Biologics appoints Thomas Montgomery Andresen as CEO | ||
| 10.03. | Lundbeck completes patient randomisation for phase 3 trial for multiple system atrophy treatment | ||
| 10.03. | Business as usual? Patient-centricity in the age of AI | ||
| 10.03. | Novo Nordisk elects employee representatives to Board of Directors | ||
| 09.03. | How HCP Interact is advancing Medical Affairs performance with AI-enabled precision | ||
| 09.03. | Johnson & Johnson's multiple myeloma treatment approved by US FDA | ||
| 06.03. | How STEM AI helps organisations understand and improve HCP interactions at scale | ||
| 06.03. | Gilead Foundation announces $12m investment through HIV Prevention Initiative | ||
| 05.03. | AI is quietly rewriting your brand narrative | ||
| 05.03. | GenAI: embracing the transformation - with caution | ||
| 05.03. | CNX Therapeutics appoints Erin Federman as non-executive director | ||
| 04.03. | J&J's nipocalimab gets FDA Fast Track designation for lupus | ||
| 03.03. | emc3 Collective launches human-centred healthcare events brand | ||
| 03.03. | Novo Nordisk to invest 432m euros to expand manufacturing facility in Ireland | ||
| 03.03. | Medivir appoints Patrik Norgren as new CFO | ||
| 02.03. | US FDA launches ultra-rare diseases framework | ||
| 02.03. | N4 Pharma appoints David Solomon as CEO | ||
| 27.02. | New report identifies stigma as a structural barrier in rare disease | ||
| 27.02. | GenAI in healthcare: why privacy and literacy matter more than the tech | ||
| 26.02. | Patient-centricity in rare disease: accelerating the path to treatment | ||
| 26.02. | Novo Nordisk and Vivtex partner in deal worth up to $2.1bn | ||
| 26.02. | AI-enabled, human-interpreted: the future of pharma marketing insights is precision intelligence | ||
| 26.02. | It's time for an end to pharma exceptionalism |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.